Balance Sheet

v3.25.0.1

Consolidated Balance Sheets - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 3,502,077	$ 1,123,604
Unbilled receivable	124,115	97,561
Prepaid expenses and other current assets	1,718,490	1,067,703
Total current assets	5,344,682	2,288,868
Other assets	252,550	419,217
Total assets	5,597,232	2,708,085
Current liabilities:
Accounts payable	1,357,079	1,936,007
Accrued expenses and other liabilities	548,458	542,260
Notes payable and accrued interest	301,660	854,697
Total current liabilities	2,207,197	3,332,964
Long-term liabilities:
Other long-term liabilities	10,096	26,388
Total long-term liabilities	10,096	26,388
Total liabilities	2,217,293	3,359,352
Commitments and contingencies (Note 6)
Stockholders’ equity (deficit)
Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at December 31, 2024 and December 31, 2023
Common stock, $0.0001 par value, 250,000,000 shares authorized at December 31, 2024 and December 31, 2023; 1,355,779 and 209,745 shares issued at December 31, 2024 and December 31, 2023, respectively; 1,355,773 and 209,739 shares outstanding at December 31, 2024 and December 31, 2023, respectively	136	21
Additional paid-in capital	133,252,585	121,234,195
Accumulated deficit	(129,544,299)	(121,557,074)
Total Ensysce Biosciences, Inc. stockholders’ equity (deficit)	3,708,422	(322,858)
Noncontrolling interests in stockholders’ deficit	(328,483)	(328,409)
Total stockholders’ equity (deficit)	3,379,939	(651,267)
Total liabilities and stockholders’ equity (deficit)	$ 5,597,232	$ 2,708,085

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Source